Open an account

Takeda Pharmaceutical

TAK · TOKYO

$20.24−$0.12 (−0.59%)TodayMarket closed ·
Prev close $20.36

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Employees
47,455
Headquarters
Chuo-Ku, Tokyo-To
Listed
May 16, 1949
Sector
Health Care
Industry
Pharmaceuticals
Website
takeda.com

TAK key statistics

Market cap
10.13T
Price-earnings ratio
0.00
Dividend yield
3.13%
Average volume
2.87M
Volume
2.10M
Open price
$20.28
High today
$20.39
Low today
$20.17
52 Week high
$20.39
52 Week low
$12.99

Takeda Pharmaceutical (TAK) at a glance

As of Oct 23, 2026, Takeda Pharmaceutical (TAK) shares are priced at $20.24, giving the company a market cap of 10.13T, a price-to-earnings ratio of 0.00 and a dividend yield of 3.13%.

Today the stock has traded between $20.17 and $20.39. The current price is 0.3% above the day's low and 0.7% below its high.

Volume so far is 2.10M shares, below the average of 2.87M shares a day.

Over the past year Takeda Pharmaceutical has ranged from $12.99 to $20.39, and now sits 98% of the way up that range.

Takeda Pharmaceutical met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY27 it reported $70.54 per share against an estimate of $54.92.

TAK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 53.9% on average.

  1. Q2 FY25: reported $58.14 per share against an estimate of $33.13
  2. Q3 FY25: reported $14.86 per share against an estimate of $25.44
  3. Q4 FY25: reported -$65.35 per share against an estimate of -$55.79
  4. Q1 FY26: reported $79.40 per share against an estimate of $57.15
  5. Q2 FY26: reported -$7.48 per share against an estimate of $34.14
  6. Q3 FY26: reported $65.65 per share against an estimate of $34.44
  7. Q4 FY26: reported -$15.56 per share against an estimate of -$24.26
  8. Q1 FY27: reported $70.54 per share against an estimate of $54.92

TAK news

  • Press releaseBusiness Wire

    Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

  • Vandana Singh

    Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

  • Press releaseBusiness Wire

    First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

  • Vandana Singh

    Ascentage Pharma Stock Could More Than Double: Analyst

  • Press releaseBusiness Wire

    Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

  • Press releaseBusiness Wire

    Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

  • Press releaseBusiness Wire

    Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

  • Press releaseBusiness Wire

    Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.